On February 14, 2023, Bracco Imaging announced a collaboration with Wellstar Health System to test VUEWAY (gadopiclenol) injection, a recent Food and Drug Administration (FDA)-approved macrocyclic gadolinium-based contrast agent (GBCA) for use in magnetic resonance imaging (MRI).
This exciting partnership places Wellstar Health System at the forefront of medical innovation, making it one of the first establishments in the U.S. to participate in this trial.
With such collaborations between healthcare providers and imaging companies, the market is experiencing exponential growth and new entrants. According to data insights from BIS Research, the global contrast media agent and injector system market was valued at $7.63 billion in 2022 and is expected to reach $9.71 billion by 2026, growing at a CAGR of 6.20% during the forecast period 2022-2026.
Click here to download a free sample
Here’s the Story-
The FDA approved VUEWAY (gadopiclenol) injection on September 21, 2022, for use in MRI scans of adults and pediatric patients aged two years and older. It is used to detect and visualize lesions in the central nervous system (spine, brain, and associated tissues) as well as the body (head and neck, abdomen, thorax, pelvis, and musculoskeletal system).
Moreover, gadopiclenol requires only half the dosage of other GBCAs currently approved in the U.S. for achieving the same level of image clarity.
The two phase-III trials, known as the PICTURE trial for central nervous system (CNS) imaging and the PROMISE trial for body imaging, demonstrated the efficacy and safety of gadopiclenol in MRI scans.
These trials involved over 500 individuals who underwent MRI scans with gadopiclenol at half the dose of a conventional agent and gadobutrol administered at the full dose. Readers found that the gadopiclenol scans had comparable image quality despite the lower dosage.
Fulvio Renoldi Bracco, vice-chairman and CEO of Bracco Imaging, said in a press release, "We're particularly excited about our innovations in contrast imaging because of the wide-reaching impact across disease categories with 30 million MRI scans conducted annually, globally. That these institutions have prioritized offering VUEWAY injection, a novel next-generation MRI contrast agent, reinforces the potential value VUEWAY injection will provide in patient care and diagnostics."
According to data from BIS Research, the MRI segment of global contrast media agent and injector system market was valued at $1.51 billion in 2021 and is expected to reach $2.20 billion by the end of 2026, registering a CAGR of 6.63% during the forecast period 2022-2026. These statistics further prove the future success of VUEWAY injection in the market.
Conclusion
Key players in the industry, such as Bracco, will likely focus on research and development to develop novel contrast agents that offer improved visibility and safety profiles.
The integration of artificial intelligence (AI) technology in medical imaging and diagnostic processes will further enhance the accuracy and efficiency of contrast-enhanced imaging. Moreover, injector systems will continue to evolve, providing more precise and automated administration of contrast agents.
These advancements will contribute to the overall growth and transformation of the market, ultimately benefiting patients and healthcare professionals alike.
Interested to know more about the growing technologies in your industry vertical? Get the latest market studies and insights from BIS Research. Connect with us at [email protected] to learn and understand more.
